Fady Hannah-Shmouni, MD, FRCPC

Dr. Fady Hannah-Shmouni, MD, FRCPC, is a board-certified clinical endocrinologist, biochemical geneticist, and physician-scientist specializing in precision medicine, with a focus on hormone biology, peptide therapy, and longevity science. He is the Founder and CEO of Hormonaly.ai, a clinical artificial intelligence platform designed to support evidence-based decision-making in endocrine and longevity medicine. His work bridges clinical practice, biomedical research, and emerging AI technologies to advance patient-centered care at scale.

Dr. Hannah-Shmouni completed his medical degree at the University of Jordan in 2009, followed by an Internal Medicine residency at Yale School of Medicine (2012–2015). He then pursued advanced fellowship training in Endocrinology and Metabolism at the National Institutes of Health (2015–2017), and later completed a fellowship in Clinical Biochemical Genetics at the University of Toronto (2017–2018). He is dual board-certified by both American and Canadian boards in Internal Medicine and Endocrinology.

Throughout his academic and clinical career, he has held multiple leadership and research roles, including Assistant Clinical Professor at the University of British Columbia. He also served as Director of the AI Academy at the Geneva College of Longevity Science, where he contributes to education in AI-driven precision medicine and longevity science. His clinical and academic interests include stress physiology, metabolic disease, rare endocrine disorders, and genetic conditions affecting hormone regulation.

In addition to his academic contributions, Dr. Hannah-Shmouni is an active researcher with over 100 peer-reviewed publications and extensive NIH-funded work, including an h-index of 28. He has authored multiple books and contributed to advancing knowledge in endocrinology, biochemical genetics, and cardiovascular-related endocrine disorders. His research continues to influence clinical approaches to complex endocrine and genetic diseases worldwide.

As an entrepreneur and physician-investor, Dr. Hannah-Shmouni has founded and advised multiple health technology companies, including DrVibe.ai, Healthspan Digital, and FHS Capital portfolio ventures. Through these initiatives, he focuses on integrating artificial intelligence into clinical workflows and expanding access to evidence-based medicine globally. His mission is to empower clinicians with intelligent tools that enhance precision medicine and improve patient outcomes in endocrinology and beyond.

• Yale School of Medicine
• University of Jordan School of Medicine - M.D., 2009
• Yale New Haven Hospital - Internal Medicine Residency
• National Institutes of Health - Endocrinology Fellowship
• University of Toronto - Genetics Fellowship

• American Board of Internal Medicine (ABIM)
• Royal College of Physicians and Surgeons of Canada (FRCPC)
• American Society of Hypertension certification

• New Investigator Award, International Society of Hypertension (2013)

• University of British Columbia (Assistant Clinical Professor)
• National Institutes of Health (former research fellow and faculty roles)
• Geneva College of Longevity Science (Director, AI Academy)
• FHS Capital (Founder & Chairman, healthtech investment group)

• Academic mentorship and training of medical trainees and fellows
• Research contributions in endocrine genetics and public health education
• Advancement of AI education for healthcare professionals globally

100+ peer-reviewed scientific publications
Research in endocrinology, metabolic disease, and biochemical genetics
Publications in journals such as JAMA, Nature Publishing Group, Circulation: Cardiovascular Genetics, and Endocrine-Related Cancer
Multiple scientific reviews on endocrine disorders, genetics, and metabolic disease mechanisms